绥美凯的最新版说明书

Instructions for Suimeikai

Drug name: Suimeikai

Generic names: Triumeq, Triumeq

Properties: Suimeikai (Domitabalamid tablets) are film-coated tablets, which appear white or off-white after the coating is removed. 

Indications: Suimeike (dolute abalamib tablets) is suitable for the treatment of adults and adolescents over 12 years old (weight at least 40kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the RLA-B*5701 allele, he should not take products containing abacavir.

How to take:

Suimeikai (Dotiabalamid Tablets) should be taken under the guidance of a physician with experience in HIV infection. Dosage Adults and Adolescents (weighing at least 40kg) For adults and adolescents, the recommended dose of Sumaxim is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced. 

Trimax (dolutegravir or lamivudine) is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir or lamivudine can be used. In these cases, physicians should refer to the respective product information for these drugs.

Missed dose: If the patient misses a dose of Suimeikan (Domitabalamid Tablets) and there are more than 4 hours before the next dose, Suimeike should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule. 

Geriatric Patients There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged 65 years and older, and there is no evidence that older patients require different doses than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when using Trimax in this age group. 

Renal damage: Patients with creatinine clearance less than 50 mL/min are not recommended to take Suimeikai (Doteta abalamide tablets). 

Hepatic Impairment: Abacavir is primarily metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment; therefore, the use of Trimax (doluteabalamide) is not recommended unless deemed necessary. For patients with mild hepatic impairment (Child-Pugh score 5-6), close monitoring is required, including monitoring of abacavir plasma levels if feasible.

  Pediatric Population: The safety and effectiveness of Suimeike (dolute abalamib tablets) in children under 12 years of age have not been established. No data yet. Dosage: Oral Trimax may be taken with or without food.

Adverse reactions: Suimeike (dolute abacavir tablets) is sometimes combined with different drugs, resulting in different adverse reactions, including nausea, vomiting, diarrhea, fever, drowsiness, rash, etc., which often occur in patients with abacavir hypersensitivity reactions.

The above is the instruction manual of Suimeikai (Doteta Abalamid Tablets), I hope it can help you!